NCT06730542 is a Phase 1 clinical trial of Zanubrutinib in CNS Lymphoma, sponsored by Juan P. Alderuccio, MD.

Who is sponsoring NCT06730542?

NCT06730542 is sponsored by Juan P. Alderuccio, MD.

What drugs are being tested in NCT06730542?

Interventions in NCT06730542: Zanubrutinib, Methotrexate, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone.

What condition does NCT06730542 study?

NCT06730542 studies CNS Lymphoma.

Is NCT06730542 still recruiting?

NCT06730542 is currently recruiting now. Last updated 8 May 2025.

Last reviewed 2025-05-08 · How we verify

NCT06730542

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

Recruiting now Phase 1 Last updated 8 May 2025

What this trial tests

Phase 1 trial testing Zanubrutinib in CNS Lymphoma in 20 participants. Currently enrolling.

Timeline

17 April 2025

Primary endpoint
30 April 2030

30 April 2030

Quick facts

Lead sponsor	Juan P. Alderuccio, MD
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	17 April 2025
Primary completion	30 April 2030
Estimated completion	30 April 2030
Sites	1 location across United States

Drugs / interventions tested

Zanubrutinib (ZANUBRUTINIB) — full drug profile →
Methotrexate
Polatuzumab Vedotin (POLATUZUMAB VEDOTIN) — full drug profile →
Rituximab — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Doxorubicin
Prednisone (prednisone) — full drug profile →

Conditions studied

CNS Lymphoma — all drugs for CNS Lymphoma →

Sponsor

Juan P. Alderuccio, MD

Who can join

18 and older, any sex, with CNS Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Zanubrutinib

Trials testing the same drug.

NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting
NCT06859008 — Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel · Phase 1 · recruiting
NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
NCT07321652 — Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C · Phase 3 · not yet recruiting
NCT07283965 — Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies · not yet recruiting

Other recruiting trials for CNS Lymphoma

Currently open trials in the same condition.

NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06876688 — Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma · Phase 2 · recruiting
NCT06132737 — [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients · Phase 1, PHASE2 · recruiting
NCT05926427 — Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Ner · Phase 2 · recruiting
NCT05351593 — Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma · Phase 1, PHASE2 · recruiting

Other Juan P. Alderuccio, MD trials

Trials by the same sponsor.

NCT04998669 — Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06730542 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juan P. Alderuccio, MD
Last refreshed: 8 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06730542.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing